Silence Therapeutics plc
SLN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001479615
No open-market purchases or sales by Silence Therapeutics plc insiders were filed in the last 90 days; 72 institutions reported holding it in 13F filings for Q2 2026, worth $236.2M in total; no superinvestor holds it.
Other share classesSLNCF
Q1 2023 vs. Q4 2022
How the institutions holding Silence Therapeutics plc changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 27 | 29 | +2 |
| Shares | 18.6M | 18.4M | −239.1K (−1.3%) |
| Value | $275.7M | $110.2M | −$165.5M (−60.0%) |
New holders (4)
Institutions that held Silence Therapeutics plc at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Artal Group S.A. | 505,074 | $3.13M | 0.19% |
| UBS Oconnor LLC | 95,383 | $591.4K | 0.01% |
| Cubist Systematic Strategies, LLC | 2,600 | $16.1K | 0.00% |
| Bank of America Corp | 550 | $3.41K | 0.00% |
Sold out (2)
Institutions that held Silence Therapeutics plc at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Adage Capital Partners GP, L.L.C. | 700,000 | $10.7M |
| SG Americas Securities, LLC | 87,987 | $1.34M |